<DOC>
	<DOCNO>NCT00917553</DOCNO>
	<brief_summary>This 24 month randomize research study evaluate whether doxycycline slow deterioration improve retinal function among patient mild moderate non-proliferative diabetic retinopathy .</brief_summary>
	<brief_title>Evaluation Effect Doxycycline Verses Placebo Retinal Function Diabetic Retinopathy</brief_title>
	<detailed_description>The objective proof-of-concept study investigate whether doxycycline slow deterioration improve retinal function among patient mild moderate NPDR ( abnormal retinal function define foveal sensitivity &lt; 30.91 dB Matrix frequency double perimetry [ FDP ] ) . Based result END DR Study , primary visual function endpoint POC 2 Study performance Matrix Frequency Doubling Technology Perimeter . This test sensitive NPDR visual function endpoint investigator evaluate END DR Study . This selection aggressive investigator lack natural history data estimate 2-year rate change endpoint ; fact , major output POC 2 Study 2-year natural history data use several visual function endpoint . The investigator enrol patient moderate dysfunction ; , patient fall outside 95 % confidence interval normal performance FDP . These patient opportunity improve FDP performance `` normal '' level well progress severe FDP impairment associate advanced disease . Secondary endpoint include visual acuity , contrast sensitivity , visual field , dark adaptation . The test perform Ophthalmology Department Penn State College Medicine . The 24-month proof-of-concept clinical study involve prospective , randomize , double-masked clinical trial include 60 adult patient type 1 type 2 diabetes mild moderate NPDR ( ETDRS level 20 43 ) , retinal photocoagulation anticipate ( investigator ) within subsequent 2 year . Participants randomize receive either doxycycline monohydrate 50mg identical placebo daily 24 month .</detailed_description>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<criteria>age ≥ 18 year old diagnosis type 1 type 2 diabetes mellitus ( define current regular use oral antihyperglycemia agent and/or insulin treatment diabetes ) hemoglobin A1c &lt; 11 % prequalification visit able willing give inform consent bestcorrected ETDRS visual acuity ( 10 ) study eye ≥ 69 letter ( 20/40 ) mild moderate nonproliferative diabetic retinopathy ( ETDRS level 20 43 ) ( 11 ) , retinal photocoagulation anticipate ( investigator ) within subsequent 2 year able perform reliable visual field dark adaptation test central subfield thickness OCT ≤ 275 micron medium clarity pupil dilation sufficient highquality fundus photograph abnormal retinal function define : abnormal FDP function define foveal sensitivity ≤ 30.91 dB prior panretinal photocoagulation study eye prior focal/grid laser photocoagulation macula study eye intraocular pressure study eye &gt; 22 mmHg Goldmann tonometry history par plana vitrectomy study eye systemic intravitreal antiVEGF agent study eye fellow eye within past 3 month peribulbar steroid injection study eye fellow eye within past 6 month intravitreal triamcinolone acetonide study eye within past 4 month expectation investigator retinal photocoagulation treatment diabetic retinopathy ( e.g. , focal/grid laser study eye , intravitreal triamcinolone acetonide study eye , intravitreal antiVEGF agent study fellow eye , ruboxistaurin systemic antiVEGF agent diabetic macular edema ) administer subsequent 24months ocular condition ( diabetes ) present study eye , opinion investigator , might alter visual acuity course study ( e.g. , retinal vein occlusion , uveitis ocular inflammatory disease , neovascular glaucoma , IrvineGass Syndrome , etc ) anticipate need cataract surgery study eye subsequent 24 month opinion investigator history major ocular surgery ( include cataract surgery , scleral buckle , intraocular surgery , etc ) study eye within prior 6 month anticipate within subsequent 24 month follow randomization aphakia study eye history YAG capsulotomy perform study eye within 2 month prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>diabetic retinopathy</keyword>
	<keyword>diabetes</keyword>
	<keyword>diabetic eye study</keyword>
</DOC>